Vol. 43 (4): 638-643, July – August, 2017

doi: 10.1590/S1677-5538.IBJU.2016.0316


Ersagun Karagüzel 1, Ahmet Menteşe 2, İlke O.Kazaz 1, Selim Demir 3, Asım Örem 4, Ali Ertan Okatan 1, Diler Us Altay 5, Serap Özer Yaman 4
1 Department of Urology, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey; 2 Program of Medical Laboratory Techniques, Karadeniz Technical University, Vocational School of Health Sciences, Trabzon, Turkey; 3 Department of Nutrition and Dietetics, Karadeniz Technical University, Faculty of Health Sciences, Trabzon, Turkey; 4 Department of Medical Biochemistry, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey 5 Department of Chemistry and Chemical Processing Technology, Ordu University, Ulubey Vocational School, Ordu, Turkey



Purpose: To investigate the efficacy of signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) as a novel biomarker of renal tumors.

Materials and Methods: 48 individuals were included in the study. The patient group (Group-1) consisted of 23 subjects diagnosed with renal tumor, and the control group (Group-2) of 25 healthy individuals. Patients diagnosed with renal tumor received surgical treatment consisting of radical or partial nephrectomy. Blood specimens were collected following overnight fasting. Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1), soluble urokinase plasminogen activator receptor (suPAR) and carbonic anhydrase IX (CA IX) levels were measured from plasma samples. Patients in groups 1 and 2 were compared in terms of these biochemical parameters.

Results: The 23-member renal tumor group was made up of 17 (73.91%) male and 6 (26.08%) female patients with a mean age of 58.5±15.7 years (range 25 to 80). The 24-member healthy control group was made up of 16 (64%) male and 9 (36%) female subjects with a mean age of 52.4±9.12 years (range 40 to 67). Analysis revealed sig­nificant elevation in SCUBE-1 levels in the renal tumor group (p=0.005). No significant differences were detected between the groups with regard to CA IX or suPAR measure­ments (p=0.062 vs. p=0.176).

Conclusions: SCUBE-1 appears to represent a promising biomarker in the diagnosis and follow-up of patients with renal tumor.

Keywords: Carcinoma, Renal Cell; Biomarkers

[Full Text]